# 1 **Identification of potential novel combination antibiotic regimens based on drug-**

- 2 **susceptibility and genetic diversity of Gram-negative bacteria causing neonatal sepsis in**
- 3 **low- and middle-income countries**
- 4

5 **Authors**: Biljana Kakaraskoska Boceska<sup>1</sup>, Tuba Vilken<sup>1</sup>, Basil Britto Xavier<sup>1,2</sup>, Christine 6 Lammens<sup>1</sup>, Sally Ellis<sup>3</sup>, Seamus O'Brien<sup>3</sup>, Renata Maria Augusto da Costa<sup>3</sup>, Aislinn Cook<sup>4</sup>, Neal 7 Russell<sup>4</sup>, Julia Bielicki<sup>4</sup>, Eitan Naaman Berezin<sup>5</sup>, Emmanual Roilides<sup>6</sup>, Maia De Luca<sup>7</sup>, Lorenza 8 Romani<sup>7</sup>, Daynia Ballot<sup>8</sup>, Angela Dramowski<sup>9</sup>, Jeannette Wadula<sup>10</sup>, Sorasak Lochindarat<sup>11</sup>, 9 Suppawat Boonkasidecha<sup>11</sup>, Flavia Namiiro<sup>12</sup>, Hoang Thi Bich Ngoc<sup>13</sup>, Tran Minh Dien<sup>13</sup>, Tim 10 R. Cressey<sup>14</sup>, Kanchana Preedisripipat<sup>15</sup>, James A. Berkley<sup>16,17,18</sup>, Robert Musyimi<sup>19</sup>, 11 Charalampos Zarras<sup>20</sup>, Trusha Nana<sup>21</sup>, Andrew Whitelaw<sup>22</sup>, Cely Barreto da Silva<sup>23</sup>, Prenika 12 Jaglal<sup>24</sup>, Willy Ssengooba<sup>25</sup>, Samir K. Saha<sup>26</sup>, Mohammad Shahidul Islam<sup>26</sup>, Marisa Marcia 13 Mussi-Pinhata<sup>27</sup>, Cristina Gardony Carvalheiro<sup>27</sup>, Laura Piddock<sup>3</sup>, Surbhi Malhotra-Kumar<sup>1</sup>,

Michael Sharland<sup>4</sup>, Youri Glupczynski<sup>1</sup>, Herman Goossens<sup>1</sup> 14

15

## 16 **Affiliations:**

- 17 <sup>1</sup>Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of
- 18 Antwerp, Antwerp, Belgium
- <sup>2</sup>STI unit, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
- <sup>3</sup>Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland
- 21 <sup>4</sup> Center for Neonatal and Pediatric Infection & Immunity, St. George's University of London,
- 22 London, United Kingdom
- <sup>5</sup> Pediatric Infectious Diseases Unit, Santa Casa de Sao Paulo, Sao Paulo, Brazil
- <sup>6</sup>Infectious Diseases Unit, 3rd Dept Pediatrics, School of Medicine, Faculty of Health Sciences,
- 25 Aristotle University and Hippokration General Hospital, Thessaloniki, Greece
- <sup>7</sup>Infectious Disease Unit, Bambino Gesu Children`s Hospital, Rome, Italy
- <sup>8</sup>Department of Pediatrics and Child Health, School of clinical Medicine, Faculty of health
- 28 Sciences, University of the Witwatersrand, Johannesburg, South Africa
- <sup>9</sup> General Pediatrics, Tygerberg Hospital, Cape Town, South Africa
- <sup>10</sup> Chris Hani Baragwanath Hospital Microbiology Laboratory, National Health Laboratory
- 31 Services, Johannesburg, South Africa
- $11$ <sup>11</sup> Oueen Sirikit National Institute of Child Health, Bangkok, Thailand
- 33 <sup>12</sup>Mulago Specialized Women's and Neonatal Hospital, Kampala, Uganda

- <sup>13</sup> 34 Vietnam National Children`s Hospital, Hanoi, Vietnam
- <sup>14</sup> Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand
- 36 <sup>15</sup>Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand
- 37 <sup>16</sup>Clinical Research Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- 38 <sup>17</sup>Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University
- 39 of Oxford, Oxford UK
- <sup>18</sup> 40 The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya
- <sup>19</sup> Department of Microbiology, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
- <sup>20</sup>Microbiology Department, Hippokration General Hospital, Thessaloniki, Greece
- 43 <sup>21</sup>Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
- 44 <sup>22</sup>Bristol Medical School, Bristol, United Kingdom
- <sup>23</sup>Infection Control and Prevention Service, Santa Casa de Sao Paulo, Sao Paulo, Brazil
- 46 <sup>24</sup>Department of Medical Microbiology, National Health Laboratory Services, School of
- 47 Laboratory Medicine and Medical Science, University of KwaZulu-Natal, Durban, South Africa
- 48 <sup>25</sup>Makerere University, Department of Medical Microbiology, Kampala, Uganda
- 49 <sup>26</sup>Child Health Research Foundation (CHRF), Dhaka Shishu Hospital, Dhaka, Bangladesh
- <sup>27</sup> Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Brazil

## **Abstract**

 **Objectives:** Several recent studies highlight the high prevalence of resistance to multiple antibiotic classes used in current treatment regimens for neonatal sepsis and new treatment options are urgently needed. We aimed to identify potential new combination antibiotic treatment regimens by investigating the drug-resistance and genetic profiles of the most frequently isolated Gram-negative bacteria causing neonatal sepsis in low- and middle-income countries (LMICs) in the NeoOBS study.

 **Material and methods:** Gram-negative bacteria isolated from neonates with culture-confirmed sepsis from 13 clinical sites in nine countries, mainly LMICs, were analyzed. Culture-based identification was followed by whole-genome sequencing (WGS). Minimal inhibitory concentrations (MICs) for 8 antibiotics were determined for a representative subset of 108 isolates.

 **Results:** Five bacterial species, *Klebsiella pneumoniae* (n=135), *Acinetobacter baumannii* (n=80), *Escherichia coli* (n=34), *Serratia marcescens* (n=33) and *Enterobacter cloacae* complex (ECC) (n=27) accounted for most Gram-negative bacterial isolates received (309/420, 74%). Extended-spectrum β-lactamases (ESBL) genes mostly belonging to CTX-M-15 were found in 107 (79%) *K. pneumoniae* isolates and 13 (38%) *E. coli*, as well as in 6 (18%) and 10 (37%) *S. marcescens* and ECC isolates, respectively. Carbapenem resistance genes were present in 41 (30%) *K. pneumoniae,* while 73 (91%) of *A. baumannii* isolates were predicted to be MDR based on carbapenem resistance genes. Apart from *A. baumannii,* in which two major pandemic lineages predominated, a wide genetic diversity occurred at the intraspecies level with different MDR clones occurring at the different sites. Phenotypic testing showed resistance to the WHO first- and second- line recommended treatment regimens: 74% of *K. pneumoniae* isolates were



## **Introduction/Background**

 In 2019, more than 560,000 neonatal deaths were associated with bacterial antimicrobial resistance (AMR), including nearly 140,000 deaths directly attributable to bacterial AMR [1]. The World Health Organization (WHO) reports that over 80% of these sepsis deaths could be prevented if there was improved treatment and infection prevention [2].

 Most of these cases occur in low- and middle-income countries (LMICs) [3]. Of the multiple large studies recently conducted in these countries [1, 4-6], one systematic review [7] and several single-site reports [8-10] have shown that Gram-negative bacteria (GNB), such as *Klebsiella* spp., *Escherichia coli* and *Acinetobacter baumannii*, are considered the main cause of neonatal sepsis in approximately 40% episodes. Furthermore, these studies have demonstrated that the empiric treatment of neonatal sepsis currently recommended by WHO, which includes a narrow-105 spectrum β-lactam antibiotic in combination with gentamicin as a first line regimen and a  $3<sup>rd</sup>$  generation cephalosporin as a second line regimen [11], is increasingly compromised by high drug resistance rates, particularly due to the high prevalence of ESBLs and of aminoglycoside modifying enzymes (AMEs). Findings from these recent studies extend data from several previous reports from LMICs where extremely high rates of resistance to amoxicillin (80%), gentamicin (60%) and third-generation cephalosporins (>80%) were observed [12-17].

 The NeoOBS study [6, 18] was a prospective, multicenter, observational cohort study investigating the management of neonatal sepsis in several countries, aiming to inform and enhance the design of the currently recruiting Global Antibiotic Research & Development Partnership (GARDP) - sponsored NeoSep1 antibiotic trial (ISRCTN48721236). The trial is investigating new antibiotic regimens for the treatment of neonatal sepsis that have activity against priority neonatal bacterial pathogens and have the potential to be available for wide use in LMICs.

 Three generic antibiotics, amikacin, flomoxef and fosfomycin were selected that met the criteria for consideration in the trial [19], and their potential to be used in novel combined empirical regimens was assessed by a dynamic hollow-fiber infection model (HFIM) and by checkerboard assays [20-22]. The three combinations, fosfomycin-amikacin, fosfomycin-flomoxef and flomoxef-amikacin exhibited synergistic interactions measured by both bactericidal killing and the prevention of emergence of resistance.

The NeoOBS microbiology sub-study aimed to determine the level of antibiotic susceptibility of

MDR Gram-negative bacteria to currently used antibiotics and to the novel drug combinations

included in the NeoSep1 trial.

**Material and Methods**

Study setting

A prospective observational clinical study of neonatal sepsis was conducted between 2018 and

2020 at 19 hospitals across 11 predominantly LMIC countries from five WHO regions (Africa,

America, Europe, Southeast Asia, and Western Pacific) [6]. Hospitalized infants <60 days of age

with an episode of clinically suspected sepsis were eligible for enrollment.

### Strain collection and characterization of isolates

The Laboratory of Medical Microbiology (LMM) at the University of Antwerp received bacterial

isolates from blood and cerebrospinal fluid (CSF) samples of neonates with culture-confirmed

sepsis from 13 participating sites in 9 countries (Supplementary Table 1). LMM did not obtain

bacterial isolates from 3 sites from India and 3 from China. All the participating sites followed a

well-established microbiological protocol for collection, storage and shipment of the isolates to

the central laboratory [18]. At LMM, species identification was verified using Microflex LT

MALDI-TOF MS (Bruker Daltonics) and the MALDI Biotyper IVD reference library (2021).

### 144 Selection of the isolates for inclusion in this microbiology study

 Identification at species level was confirmed by WGS for 723 out of 1051 bacterial isolates. Gram positive were 303 (Coagulase-negative staphylococci (n=254) and *Staphylococcus aureus*, n=49), and 420 were Gram-negative, belonging to 23 different species. Enterobacterales, comprising *Klebsiella pneumoniae* (n=135), *Escherichia coli* (n=33), *Serratia marcescens* (n=34) and *Enterobacter cloacae* complex (n=27), as well as *Acinetobacter baumannii* (n=80) as non-fermenters, were the most common pathogens, together accounting for nearly three- quarters of Gram-negative isolates. The focus of this study was limited to Gram-negative bacteria. For all analyses, the patient's first clinical isolate from blood or CSF was selected. In case of

 mixed infection, isolates belonging to different species were also included. To avoid analyzing replicates of the same bacterial clone, only isolates displaying different genetic profiles were selected for *in vitro* susceptibility testing. Isolates belonging to a given species for which less than 20 isolates were obtained were not further analyzed.

## DNA isolation and Whole Genome Sequencing (WGS)

 Genomic DNA isolation was done using the MasterPure complete DNA and RNA purification kit (Epicentre, Madison, WI, USA). Library and sample preparation were performed using Nextera XT sample preparation kit (Illumina) and for sequencing MiSeq (Illumina Inc., USA) was used. The raw data of the sequenced strains were quality checked and trimmed using trimmomatic v0.4.2. The second analysis was performed using BacPipe v.1.2.6 [23]. Built-in tools and databases were used for *de novo* assembly SPAdes (v.3.11.0) and Prokka (v1.11.1) for annotation. Assembled contigs were quality checked using checkM [24]. MLST for *E. coli* [25], *K. pneumoniae* [26], *Enterobacter* spp. [27] and *Acinetobacter* spp. [28] were determined

 according to MLST schemes of organism-specific reference databases. For core genome multilocus sequence typing (cgMLST), a gene-by-gene approach was utilized by developing a custom scheme for the specific study, assessing allelic loci distances using ChewBBACA [29]. Clonal relatedness was defined as ≤10 allelic differences between isolates for *A. baumannii* [29] and <12 for *Klebsiella* spp. [30]. Trees were visualized using Grapetree [31]. For strains for which phenotypic MIC susceptibility testing was not performed, the presence of one or more resistance genes to the tested antibiotics was used to reflect resistance. *In vitro* susceptibility testing Eighty-seven *K. pneumoniae* and 21 *E. coli* isolates representing different genetic profiles were

 tested against first- and second- line WHO-recommended regimens (ampicillin, gentamicin and cefotaxime), as well as piperacillin-tazobactam, meropenem and three antibiotics (flomoxef, amikacin and fosfomycin) that are under investigation as a potential new regimen in combination. The activity of fosfomycin was assessed by agar dilution method. All tests were performed according to the latest guidelines of the EUCAST susceptibility testing standards and 182 interpretation criteria [\(https://www.eucast.org/clinical\\_breakpoints\)](https://www.eucast.org/clinical_breakpoints).

 For flomoxef, in the absence of formal EUCAST/CLSI clinical breakpoint, we used an MIC 184 susceptibility breakpoint of  $\leq 1$  mg/L, based on a large retrospective study in patients with bacteremia due to ESBL producers, which reported a more favorable clinical outcome in patients 186 treated with flomoxef when isolate MICs were  $\leq 1$  mg/L compared to those with MICs  $\geq 2$  mg/L [32].

 The susceptibility of the isolates to the proposed combination regimens was analyzed based on the novel combination breakpoint thresholds determined by HFIM model and checkerboard assays [20-22]. If flomoxef MIC values are between 1 and 32 mg/L, combination with fosfomycin or amikacin extends flomoxef's spectrum of activity, but only when MIC of the associated drug is in the range of the corresponding MIC breakpoints, i.e. ≤32 mg/L for

```
193 fosfomycin and ≤16 mg/L for amikacin [20, 21]. Success of fosfomycin-amikacin combination
```
194 is predicted if the product of the two individual antibiotic MICs is  $\leq$ 256 mg/L [R. da Costa, personal communication, August 31, 2023].

## **Results**

- In total, 420 Gram-negative bacterial isolates were received. The five most common identified
- species were: *K. pneumoniae* (n=135), *A. baumannii* (n=80), *E. coli* (n=34), *S. marcescens*
- (n=33) and *Enterobacter cloacae* complex (ECC) (n=27). These 309 Gram-negative isolates
- were obtained from 295 patients. The remaining 111/420 GNB isolates belonged to 18 different
- bacterial species were represented by less than 20 isolates each. The distribution of the five major
- GNB isolates per sites is shown in Figure 1.







**species analyzed by site**.

(n=309, one isolate per species per patient only, following removal of duplicates).

(number of isolates correlates with the number of neonates, except for the following sites: TH13

(13 neonates - 14 isolates), SA12 (46 neonates - 51 isolates), SA11 (51 neonates - 56 isolates),

SA10 (75 neonates - 77 isolates) and BR2 (5 neonates - 6 isolates)).

## **Antibiotic susceptibility testing and resistance mechanisms**

Ampicillin/gentamicin regimen had low rates of coverage, with 32% (34/108) of the isolates

susceptible, and only 22% (24/108) susceptible to cefotaxime (Supplementary Table 2).

*K. pneumoniae* was the species with highest rates of resistance due to the high prevalence of

ESBLs and of AMEs, found in 74% (64/87) and 63% (55/87) of the isolates, respectively. The

rates of susceptibility to piperacillin-tazobactam differed between *K. pneumoniae* (35%) and *E.* 

219 *coli* (67%) due to the frequent occurrence of the  $bla_{\text{OXA-1}}$  gene among *K. pneumoniae* isolates.

Carbapenem resistance was almost exclusive *to K. pneumoniae*, with 30% (26/87) strains

resistant to meropenem versus 5% (1/21) of *E. coli*. The most prevalent carbapenem resistance

222 genes were NDM-like  $(81\%; n=21/26)$ , followed by OXA-48-like  $(11\%; n=3/26)$ .

 Susceptibility rates to flomoxef (71%) and amikacin (70%) were comparable to those observed for meropenem (75%) in the subset of 108 isolates with available MIC results. Flomoxef displayed good activity against ESBL-producing Enterobacterales (ESBL-PE) and resistance to 226 this agent was due to class C  $\beta$ -lactamases and carbapenemases. Among the aminoglycosides, amikacin showed the best activity against ESBL-PE, since it was not affected by common AMEs (AAC(3)-II, ANT(2')-I), which are known to modify gentamicin. Fosfomycin showed the strongest antibacterial activity with 90% of the phenotypically tested isolates being susceptible to this antibiotic. An almost perfect match (106/108) was found between susceptibility and resistance phenotypes and genotypes for all beta-lactams, including broad-spectrum penicillins, cephalosporins and carbapenem drugs, as well as for aminoglycosides. All ESBLs, AmpC and carbapenem resistance genes detected by genotyping correctly predicted strain susceptibility 234 patterns, except for one *K. pneumoniae* isolate carrying the  $bla_{NDM-1}$  gene but found to be

 susceptible to meropenem (MIC of 0.06 mg/L). For aminoglycosides, all strains carrying resistance genes coding for modifying enzymes to gentamicin and/or to amikacin were confirmed as resistant to these drugs by MIC testing. All strains coding for 16S rRNA methylase genes 238 displayed high level resistance to gentamicin and to amikacin ( $MIC > 256$  mg/L for both agents). One *K. pneumoniae* isolate displayed high-level resistance to amikacin (MIC >256 mg/L) but did not contain a resistance gene that accounts for resistance to amikacin. Among the 11 fosfomycin-resistant strains, only two carried the gene encoding the fosfomycin-modifying enzyme (*fosA3* in one *E. coli* isolate with a fosfomycin of MIC >512 mg/L and *fosA5* in one *K. pneumoniae* isolate with an MIC of 64 mg/L). Besides *fosA3* and *fosA5*, genes coding other fosfomycin-modifying enzymes (*fosB*, *fosC*, *fosX*) were not found in the resistant strains. Also, no mutations of cell-wall transport systems (*glpT* and *uhpT*), their respective regulatory genes (*cyaA* and *ptsI*) nor *murA* targets were present in any of these strains.

 The rates of susceptibility to the proposed new regimens were assessed using the novel combination breakpoint thresholds determined by HFIM assays [20-22]. For Enterobacterales isolates for which MIC determination was performed, prediction of susceptibility to at least one antibiotic combination was 77/108 (71%) isolates for flomoxef-amikacin, 85/108 (79%) for fosfomycin-amikacin and 82/108 (76%) for flomoxef-fosfomycin compared to 34/108 (31%) for ampicillin-gentamicin and 24/108 (22%) for cefotaxime (Table 1 and Supplementary Table 2). The three new combinations exhibited strong activity against ESBL-producing *E. coli* and *K. pneumoniae* isolates (excluding those strains producing an AmpC cephalosporinase and carbapenemase in addition to ESBL) and an excellent coverage with flomoxef-amikacin and flomoxef-fosfomycin of 100% (n=52/52) and 92% (n=48/52) with fosfomycin-amikacin combinations**.**

## 259 **Table 1. Susceptibility of 108 Enterobacterales isolates to different combination regimens**



## 260 **based on the novel combination breakpoint thresholds [20-22]**

261 \* *Klebsiella pneumoniae* (n=87), *Escherichia coli* (n=21)

262 ° FOS: fosfomycin, FLX: flomoxef, AMK: amikacin

263 \*\* Among the 26 meropenem-resistant, carbapenemase-producing Enterobacterales isolates, 21 264 were concomitantly ESBL-producing and 5 were ESBL-negative.

265

266 Susceptibility of *S. marcescens* and ECC was predicted by the presence of resistance genes. Both

267 species harbored genes coding for inducible chromosomal AmpC and displayed resistance to

268 cefotaxime, as well as to flomoxef alone. In addition, genes coding for ESBLs were observed in

269 6/33 (18%) of *S. marcescens* and 10/27 (37%) of ECC isolates. Resistance to gentamicin was

270 predicted in 4/33 (12%) of *S. marcescens* and in 10/27 (37%) of ECC.

271 The activity of amikacin was predicted to cover 91% of *S. marcescens* and 96% of ECC isolates,

272 since genes coding for AMEs or for 16SrRNA methylase genes that confer resistance to this

273 antibiotic were not widespread. Carbapenem resistance was predicted to be low, as only one

274 isolate per species was found to carry an NDM-like gene.

275 Among *A. baumannii* isolates, 91% (73/80) harbored OXA-like carbapenemase genes (mostly

276 OXA-23 and OXA-58) and 45% (36/80) co-harbored NDM-1 always in association with OXA-

 23, as well as resistance genes to several other classes of antimicrobials, including the 16S rRNA methylase genes, that confers high-level resistance to all aminoglycosides for clinical use.

## **Characterization of** *Klebsiella pneumoniae*

 *K. pneumoniae* isolates were found in all 13 sites, and WGS analysis revealed high genetic diversity with a total of 56 different sequence types (STs) found among the 135 isolates obtained. Fifty-seven isolates belonging to 12 STs were predicted to be MDR, based on the presence of acquired drug resistance genes to 3 or more classes of antimicrobial agents. These MDR *K. pneumoniae* clones were isolated at all sites but with different geographic distribution of STs (Table 2). For instance, the predominant STs in South African sites were ST39, ST17 and ST14, while ST15 and ST147 were found in Vietnam and Bangladesh, respectively. As illustrated in Table 2, *K. pneumoniae* belonging to different STs were often co-circulating at different sites. 

#### 298 **Table 2. Distribution of the 12 most prevalent MDR STs of** *K. pneumoniae* **by site.**

299

	Sequence types*												
<b>Site</b>							ST39 ST17 ST14 ST307 ST37 ST11 ST147 ST15 ST101			ST14- 1LV	ST15- 1LV		ST20 Total
BA1							3						6
BR <sub>2</sub>						$\mathcal{D}_{\cdot}$							2
BR <sub>3</sub>													0
GR4													
IT <sub>8</sub>													
KE <sub>9</sub>													
<b>SA10</b>			3										4
<b>SA11</b>	12	3											16
<b>SA12</b>		7	5	$\overline{2}$									15
<b>TH13</b>				$\overline{2}$									3
<b>TH14</b>													$\boldsymbol{0}$
<b>UG15</b>				$\mathbf{1}$									3
VI16								3	1				6
<b>Total</b>	14	12	9	5	4	3	3	3	1			1	57

<sup>300</sup>

301 \*The presence of more than one isolate belonging to the same sequence type at a given site 302 indicates clonal spread

303

 CgMLST revealed that isolates of the same ST found at different sites could be delineated in different clones (Figure 2). This analysis had, as expected, a much higher discriminatory power than classical multilocus sequence typing and it allowed the detection of distinct clones within a single ST, most notably for ST39, ST14 and ST17.



**Figure 2. Minimum spanning tree of cgMLST analysis of MDR clones of** *K. pneumoniae* 

### **(n=57) showing specific local site clustering.**

- Left: ST based clustering Right: Site based clustering. The white circles represent public references.
- 

In total, 83% (112/135) of *K. pneumoniae* isolates carried one or several ESBL genes encoding

resistance to extended spectrum cephalosporins; this was confirmed phenotypically for 65/87

- isolates (44 ESBL only and 21 in association with carbapenamase) tested phenotypically. ESBL
- 318 coding genes were widely distributed and found in isolates from  $12/13$  sites; the *blact*<sub>X-M-15</sub> gene

was the most prevalent ESBL, present in 96 isolates at 10 sites. Other less frequently found ESBL

- genes were *bla* CTX-M-14 (in 7 isolates), *bla* CTX-M-27 (in 2 isolates) both at site VI16 in Vietnam,
- *blas<sub>HV</sub>* (in 5 isolates) and *bla<sub>TEM</sub>* (in 2 isolates).

322 On the contrary, only six isolates carried AmpC genes,  $bla_{MOX-2}$  (n=3, site GR4) and  $bla_{DHA-1}$ 

- (n=3 from BA1, TH13 and VI16).
- All strains with carbapenemase coding genes were phenotypically resistant. These strains were
- found at 7 sites across five countries (Figure 3). The most frequent carbapenem resistance gene
- 326 was *bla*<sub>NDM</sub> being identified in 31/135 (23%) of *K. pneumoniae* isolates. Among the different

327 variants,  $bla_{NDM-1}$  was the most prevalent (n=20) but other alleles ( $bla_{NDM-4}$  and  $bla_{NDM-5}$ ) were also found. As known from the epidemiology of carbapenemase producers, specific carbapenem resistance genes were associated with the geographic areas in which the isolates were found. Despite the small number of isolates, KPC producing strains were mostly found in Brazil, those carrying OXA-48-like carbapenemase in Bangladesh (BA1) and South Africa (SA11) and those with NDM-4 and NDM-5 in South-East Asia (VI16) and Asia (BA1) (Figure 3).





**Figure 3. Distribution of carbapenem resistance genes of** *K. pneumoniae* **isolates (n=135)** 

**by site.**

 (n) = total number of *K. pneumoniae* isolates per site. Sites that collected *K. pneumoniae* isolates lacking any carbapenem resistance genes are not shown in this figure (UG15 n=5, GR4 n=4, KE9 n=4, IT8 n=3, BR3 n=3 and TH14 n=2).

Acquired aminoglycoside resistance genes were found in 122/135 (90%) *K. pneumoniae* isolates

- (Figure 4), usually in association with ESBL- and/or with carbapenemase-coding genes. In
- particular the *aac(3)-II* genes which confers resistance to gentamicin, were frequently present
- (n=90; 67%), most often in association with  $blac_{\text{TX-M-15}}$  ESBL gene (n=78). Other genes like





- 347 methylases (*armA, rmtB, rmtC, rmtF*), which are known to confer resistance to all clinically used
- 348 aminoglycosides, were identified in 23 isolates from 5 sites (BA1, SA10, SA11 SA12 and VI16)
- 349 (Figure 4). The 16S rRNA methylase genes were carried only by carbapenemase-producing
- 350 isolates, mostly NDM-producers.
- 351



#### 353 **Figure 4. Distribution of aminoglycoside resistance genes of** *K. pneumoniae* **isolates (n=135) by site.**

 (n) = total number of *K. pneumoniae* isolates per site found. Two sites that collected *K. pneumoniae* isolates (BR3 n=3 and TH14 n=2) but without aminoglycoside resistance genes being detected are not represented in this figure. Several isolates were carrying more than one resistance gene to a given class of antimicrobial agents. Other aminoglycoside resistance genes: *aadA, aph(6')-I* (streptomycin resistance) and *aph(3')-I* (neomycin/kanamycin resistance) were very frequent but are not represented in this figure due to their lack of clinical relevance in 360 humans.

361

### 362 **Characterization of** *E. coli*

- Thirteen different *E. coli* STs were identified. ST1193 (n=13, 38%) was the most abundant in
- isolates from Vietnam (VI16, n=5) and one site in South Africa (SA11, n=4). The second most
- prevalent ST type was ST131 (n=5, 15%), reported from two sites in South Africa (SA10, n=1

366 and SA12, n=2), Thailand (TH13, n=1) and Vietnam (VI16, n=1).

- Compared to *K. pneumoniae, E. coli* isolates carried fewer antibiotic resistance genes. Thirty-
- 368 eight percent of the isolates (13/34) harbored an ESBL gene, mostly *blactx-M-27* (n=8) and *blactx-*
- <sub>M-15</sub> (n=5) genes. Only one isolate carried a *bla*<sub>KPC-2</sub> carbapenem resistance gene (site VI16) and
- 370 one with AmpC gene (*blac<sub>MY-2</sub>*, site TH13).
- Aminoglycoside resistance genes were detected in 9 *E. coli* isolates from 5 sites. Genes encoding
- AMEs modifying only gentamicin (*aac(3)-II* and *ant(2')-Ia*) were observed in 7 isolates and were
- found in association with ESBL genes mostly in ST131 or in ST1193. Furthermore, two *E. coli*
- strains from site VI16 carried the *rmtB* 16S RNA methylase gene leading to resistance to all

aminoglycosides including amikacin.

## **Characterization of** *A. baumannii*

 In *A. baumannii*, 13 different sequence types were identified, with two of them predominant: ST1 (n=36) and ST2 (n=24). These two STs represent the two major international pandemic lineages, GC1 and GC2, respectively. Two sites from South Africa (SA10 and SA12) accounted for 80% of the *A. baumannii* isolates. Two different clusters could be delineated within ST1 and ST2 each (Figure 5). While the ST2 strains were grouped in two distinct clusters and differed between sites SA10 and SA12, the ST1 strains of these two sites were also grouped in two different clusters, but closely related to each other with a small allelic loci distance (Figure 5). Other sporadic STs not associated with pandemic lineages were found at single sites.



**Figure 5. Minimum spanning tree from** *A. baumannii* **genomes (n=80) by cgMLST** 

**sequence types (STs).**

 Left: The MLST groups (Pasteur scheme). Right: The sequence type diversity by site*.* White circles indicate the public references. 

 *A. baumannii* isolates displayed a very extensive drug resistance profile. Carbapenemase- producing *A. baumannii* isolates were found in 8 sites in 5 countries in Asia and Africa (Figure 6). *BlaO*XA23 was the most frequently present carbapenem resistance gene, present in 64/80 (80%) 395 of the isolates and nearly half of the OXA-23-producers  $(n=36; 45%)$  co-carried  $bla_{NDM-1}$ . Ten 396 isolates (13%), seven of which from site SA12, were carrying a  $bla_{\text{OXA-58}}$  gene (Figure 6). All 397 ST1 isolates from sites SA10, SA11 and SA12 in South Africa always carried the *bla*<sub>NDM-1</sub> and *bla*OXA-23 genes. On the other hand, strains belonging to ST2 carried *bla*OXA-23 alone and never in 399 association with  $bla_{NDM-1}$ . Most of the  $bla_{OXA-58}$  positive isolates (n=10) were associated with ST243 and were found almost exclusively at site SA12 (n=7; 70%).



#### **Figure 6. Distribution of carbapenem resistance genes in** *A. baumannii* **isolates (n=80) by site.**

 Site UG15 (n=1) not represented in the chart since one unique *A. baumannii* isolate lacking any acquired carbapenemase producing genes.

 More than 90% (74/80) of the *A. baumannii* isolates harbored one or several resistance mechanisms to all aminoglycosides including amikacin (Figure 7). The *armA* rRNA 16S methylase gene (in 53/80 strains, 62%) often in association with *aac(3)-Ia* (in 35/80 strains, 44%), was the most common aminoglycoside resistance mechanism.





 **Figure 7. Distribution of aminoglycoside resistance genes of** *A. baumannii* **isolates (n=80) per site.**

(n) = total number of *A. baumannii* isolates collected per site. *aph(3')-VI* (n=2) and *aph(3')-VIa*

(n=17) grouped together. Several isolates were carrying more than one resistance gene to a

given class of antimicrobial agents.

### **Characterization of** *Enterobacter cloacae* **complex (ECC)**

ECC isolates (n=27) were collected at 12 sites in 8 countries with different subspecies occurring

at the different sites. *E. hormaechei* (n=15) was the most common species found at 8 sites; *E.* 

*roggenkampii* (n=4) at two and *E. asburiae* (n=3) at 3 sites. Antimicrobial resistance in ECC is

partly due to intrinsic chromosomal genes. All strains had in their core genome different alleles

423 of *bla*<sub>ACT</sub>, an intrinsic AmpC gene that when overexpressed leads to resistance to expanded

spectrum cephalosporins.

425 Multiple acquired resistance genes were found in 10/27 (37%) of the ECC isolates. All of these

multidrug resistant strains were identified genetically as *E. hormaechei*. These strains belong to

five different ST types including the well-known ST68 and ST78 MDR lineages. Nine of the 10

428 ESBL-producing *E. hormaechei* isolates carried a *bla*<sub>CTX-M-15</sub> and one a *bla*<sub>SHV-12</sub> gene. Other 429 resistance genes that were frequently found in association with ESBLs were *bla*<sub>OXA-1</sub> gene (resistance to piperacillin-tazobactam) and *aac(3)-II* coding genes (resistance to gentamicin). 431 One of the 10 strains collected at site BA1 was also carrying a *bla*<sub>NDM-1</sub> gene and a *rmtB* 16S rRNA methylase gene rendering it almost pan-resistant.

## **Characterization of** *Serratia marcescens*

Thirty-three *Serratia marcescens* isolates were collected from 7 sites in 6 countries, majority

(n=19; 58%) from the two South African sites. The cgMLST analysis highlighted the diversity

of the *S. marcescens* isolates, between the different sites but also within single sites.

438 Genes coding for ESBLs,  $bla_{VEB-5}$  (n=2),  $bla_{CTX-M-14}$  (n=2) and  $bla_{CTX-M-15}$  (n=2) were found in 6

(18%) isolates in Vietnam (n=3), Bangladesh (n=2), and Thailand (n=1). One isolate from

440 Vietnam harbored a *bla*<sub>NDM-5</sub> carbapenem resistance gene.

 16S rRNA methylase genes (*armA* (n=2); *rmtB* (n=1)) were found in three isolates at two sites, BA1 and VI16.

## **Discussion**

 Three generic antibiotics, flomoxef, amikacin and fosfomycin, were evaluated in novel combinations as new empiric carbapenem-sparing regimens for the treatment of neonatal sepsis, exhibited very good activity against the majority of these Enterobacterales isolates. The NeoOBS clinical study documented Gram-negative bacteria as the most common causative pathogens in neonatal sepsis [6], which is consistent with recent literature in LMICs [33]. The most frequently isolated species were *K. pneumoniae* and *A. baumannii,* a finding which is also in line with data

 by others from several single and multicenter studies of neonatal sepsis in LMICs [4, 5, 7, 9, 34- 36]. *A. baumannii* isolates were predicted to be extremely drug-resistant as they harbored a large array of genes conferring resistance to almost all classes of antibiotics, leaving colistin as the only therapeutic option for neonatal sepsis caused by this organism. Among Enterobacterales, resistance to β-lactams was due to the widespread distribution of ESBLs, especially among *K. pneumoniae* (79%) and *E. coli* (38%) isolates. Piperacillin-tazobactam, that provides partial ESBL/pseudomonal coverage and was commonly used as empirical treatment by some hospitals [6], had moderate antibacterial activity against *E. coli* (susceptibility of 67%) but low activity 459 against *K. pneumoniae* (susceptibility of 35% only), due to the widespread distribution of *bla*<sub>OXA</sub>

 <sup>1</sup>. These high rates of antimicrobial resistance have been translated to the increased use of meropenem for treatment of these patients with sepsis at these sites. However, in this study resistance to meropenem was also observed in approximately 30% of *K. pneumoniae* isolates.

 All isolates in this study showed wide genetic diversity, especially *K. pneumoniae* isolates, with 56 different STs in 135 isolates. Multidrug resistant strains belonged to different lineages and clones. Most of these isolates belong to multidrug-resistant international lineages that are already widely reported in both adults and neonates, and are known to be associated with nosocomial outbreaks and endemic hospital settings [37-39]. Besides their ability to spread through clonal expansion, these MDR lineages are also known to carry several plasmids, transposons and other mobile genetic elements that allow them to acquire and spread antimicrobial resistance within and across different bacterial species [40].

 In *E. coli*, ST131 and ST1193 accounted as the most frequent STs in the NeoOBS study. This is in line with a recent epidemiological study which found that next to ST131, ST1993 is the second most widely globally distributed MDR clone recorded to date [41]. Interestingly, we found that *E. coli* ST1193 was also largely distributed in different sites from Vietnam to Kenya, Uganda and South Africa, highlighting the expansion of this lineage also on the African continent.

Multi-drug resistant *A. baumannii* strains were unevenly distributed at 8 sites, but found in large

numbers at only two of the participating sites (SA10 and SA12).

 *A. baumannii* has emerged during the last decade as a major difficult to treat nosocomial bacterial pathogen which is often linked with outbreaks or endemic contexts in healthcare settings. Once established, this organism can persist in the healthcare environment and is extremely difficult to eradicate [42]. Unlike *K. pneumoniae* and *E. coli* which showed high genetic diversity, *A. baumannii* isolates were less diverse and mostly belonged to the two dominant pandemic international clonal groups (CG1 and CG2) known to occur in a limited number of sites, mostly in South Africa.

 Susceptibility of *S. marcescens* and ECC was inferred from genotyping of resistance genes. Both species had inducible chromosomal AmpC genes and showed resistance to the WHO second-line cephalosporin regimen (cefotaxime/ceftriaxone) as well as to flomoxef alone. It is well known from the literature that derepressed mutants can be selected in AmpC inducible species during therapy with these agents and lead to the development of resistance and clinical failure, especially in invasive infection caused by *Enterobacter cloacae* complex [43].

 Although the study recruited over 3200 neonates, the limitations of this study mainly relate to the relatively small number of samples obtained, especially from sites where lower number of patients were enrolled. Besides differences in the prevalence and distribution of neonatal sepsis pathogens, variation in blood culture positivity rates between centers was also observed [6], possibly indicating differences in the collection and/or performance of microbiological methods used locally. The majority of neonatal units participating in this study were from tertiary hospitals in urban areas, so the burden of AMR may not be representative for district hospitals. These elements represent an important bias in most AMR studies in low-resource settings, where the need for high-quality microbiology means that certain settings may be overrepresented.

# **Conclusion**



## **References**

- 1. Antimicrobial Resistance, C., *Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.* Lancet, 2022. **399**(10325): p. 629-655.
- 2. Organization, W.H., *Global report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions.* 2020.
- 3. Gan, M.Y., et al., *Contemporary Trends in Global Mortality of Sepsis Among Young Infants Less Than 90 Days: A Systematic Review and Meta-Analysis.* Front Pediatr, 2022. **10**: p. 890767.
- 4. Sands, K., et al., *Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries.* Nat Microbiol, 2021. **6**(4): p. 512-523.
- 5. Investigators of the Delhi Neonatal Infection Study, c., *Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study.* Lancet Glob Health, 2016. **4**(10): p. e752-60.
- 6. Russell, N.J., et al., *Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS).* PLoS Med, 2023. **20**(6): p. e1004179.
- 7. Okomo, U., et al., *Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.* Lancet Infect Dis, 2019. **19**(11): p. 1219-1234.
- 8. Ullah, O., et al., *Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan.* Arch Iran Med, 2016. **19**(12): p. 866-869.
- 9. Hamer, D.H., et al., *Etiology of bacteremia in young infants in six countries.* Pediatr Infect Dis J, 2015. **34**(1): p. e1-8.
- 10. Dramowski, A., A. Madide, and A. Bekker, *Neonatal nosocomial bloodstream infections at a referral hospital in a middle-income country: burden, pathogens, antimicrobial resistance and mortality.* Paediatr Int Child Health, 2015. **35**(3): p. 265-72.
- 11. Fuchs, A., et al., *Reviewing the WHO guidelines for antibiotic use for sepsis in neonates and children.* Paediatr Int Child Health, 2018. **38**(sup1): p. S3-S15.
- 12. Labi, A.K., et al., *Neonatal bloodstream infections in a Ghanaian Tertiary Hospital: Are the current antibiotic recommendations adequate?* BMC Infect Dis, 2016. **16**(1): p. 598.
- 13. Bandyopadhyay, T., et al., *Distribution, antimicrobial resistance and predictors of mortality in neonatal sepsis.* J Neonatal Perinatal Med, 2018. **11**(2): p. 145-153.
- 14. Jajoo, M., et al., *Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in North India.* PLoS One, 2018. **13**(6): p. e0180705.
- 15. Yadav, N.S., et al., *Bacteriological profile of neonatal sepsis and antibiotic susceptibility pattern of isolates admitted at Kanti Children's Hospital, Kathmandu, Nepal.* BMC Res Notes, 2018. **11**(1): p. 301.
- 16. Pokhrel, B., et al., *Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal.* BMC Pediatr, 2018. **18**(1): p. 208.
- 17. Chaurasia, S., et al., *Neonatal sepsis in South Asia: huge burden and spiralling antimicrobial resistance.* BMJ, 2019. **364**: p. k5314.
- 18. Riddell, A., et al., *Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting.* Antibiotics (Basel), 2023. **12**(5).
- 19. Darlow, C.A., et al., *Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.* Paediatr Drugs, 2021. **23**(5): p. 465-484.

- 20. Darlow, C.A., et al., *Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.* Antimicrob Agents Chemother, 2021. **65**(7): p. e0029321.
- 21. Darlow, C.A., et al., *Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.* J Antimicrob Chemother, 2022. **77**(5): p. 1334-1343.
- 22. Darlow, C.A. and W. Hope, *Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.* J Antimicrob Chemother, 2022. **77**(3): p. 711-718.
- 23. Xavier, B.B., et al., *BacPipe: A Rapid, User-Friendly Whole-Genome Sequencing Pipeline for Clinical Diagnostic Bacteriology.* iScience, 2020. **23**(1): p. 100769.
- 24. Parks, D.H., et al., *CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes.* Genome Res, 2015. **25**(7): p. 1043-55.
- 25. Wirth, T., et al., *Sex and virulence in Escherichia coli: an evolutionary perspective.* Mol Microbiol, 2006. **60**(5): p. 1136-51.
- 26. Diancourt, L., et al., *Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates.* J Clin Microbiol, 2005. **43**(8): p. 4178-82.
- 27. Jolley, K.A. and M.C. Maiden, *BIGSdb: Scalable analysis of bacterial genome variation at the population level.* BMC Bioinformatics, 2010. **11**: p. 595.
- 28. Diancourt, L., et al., *The population structure of Acinetobacter baumannii: expanding multiresistant clones from an ancestral susceptible genetic pool.* PLoS One, 2010. **5**(4): p. e10034.
- 29. Fitzpatrick, M.A., E.A. Ozer, and A.R. Hauser, *Utility of Whole-Genome Sequencing in Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks.* J Clin Microbiol, 2016. **54**(3): p. 593-612.
- 30. Kluytmans-van den Bergh, M.F., et al., *Whole-Genome Multilocus Sequence Typing of Extended-Spectrum-Beta-Lactamase-Producing Enterobacteriaceae.* J Clin Microbiol, 2016. **54**(12): p. 2919-2927.
- 31. Zhou, Z., et al., *GrapeTree: visualization of core genomic relationships among 100,000 bacterial pathogens.* Genome Res, 2018. **28**(9): p. 1395-1404.
- 32. Lee, C.H., et al., *Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia.* Infect Drug Resist, 2018. **11**: p. 2471-2480.
- 33. Wen, S.C.H., et al., *Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis.* PLoS Med, 2021. **18**(9): p. e1003787.
- 34. van Staaden, H., C. Hendricks, and K. Spicer, *Bacteraemia and antibiotic sensitivity in a tertiary neonatal intensive care unit.* S Afr J Infect Dis, 2021. **36**(1): p. 195.
- 35. Pillay, D., et al., *Neonatal sepsis in a tertiary unit in South Africa.* BMC Infect Dis, 2021. **21**(1): p. 225.
- 36. Mulinganya, G.M., et al., *Etiology of Early-Onset Neonatal Sepsis and Antibiotic Resistance in Bukavu, Democratic Republic of the Congo.* Clin Infect Dis, 2021. **73**(4): p. e976-e980.
- 37. Safavi, M., et al., *Global genotype distribution of human clinical isolates of New Delhi metallo-beta-lactamase-producing Klebsiella pneumoniae; A systematic review.* J Glob Antimicrob Resist, 2020. **23**: p. 420-429.
- 38. Mbelle, N.M., et al., *Pathogenomics and Evolutionary Epidemiology of Multi-Drug Resistant Clinical Klebsiella pneumoniae Isolated from Pretoria, South Africa.* Sci Rep, 2020. **10**(1): p. 1232.

- 39. Osei Sekyere, J. and M.A. Reta, *Genomic and Resistance Epidemiology of Gram- Negative Bacteria in Africa: a Systematic Review and Phylogenomic Analyses from a One Health Perspective.* mSystems, 2020. **5**(6).
- 40. David, S., et al., *Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among Klebsiella pneumoniae.* Proc Natl Acad Sci U S A, 2020. **117**(40): p. 25043-25054.
- 41. Pitout, J.D.D., et al., *Escherichia coli ST1193: Following in the Footsteps of E. coli ST131.* Antimicrob Agents Chemother, 2022. **66**(7): p. e0051122.
- 42. Medioli, F., et al., *Is It Possible to Eradicate Carbapenem-Resistant Acinetobacter baumannii (CRAB) from Endemic Hospitals?* Antibiotics (Basel), 2022. **11**(8).
- 43. Meini, S., et al., *AmpC beta-lactamase-producing Enterobacterales: what a clinician should know.* Infection, 2019. **47**(3): p. 363-375.